**5. Conclusion**

The search for compounds that can stabilize the KRas4B/PDE6δ heterodimeric complex has provided a great pattern in the search for new and less toxic pharmacological alternatives for the treatment of pancreatic cancer and with fewer collateral effects due to their high specificity. Compounds D14 and C22 have shown great specific cytotoxic effects against pancreatic cancer cell lines as well as decreased tumor growth and, even better, in the possible reduction of the PCSC population. However, it is necessary to carry out additional experiments in order to identify the specific mechanisms of action of the cross-linking and stabilizing compounds of this protein multicomplex.
